NO118375B - - Google Patents
Download PDFInfo
- Publication number
- NO118375B NO118375B NO159154A NO15915465A NO118375B NO 118375 B NO118375 B NO 118375B NO 159154 A NO159154 A NO 159154A NO 15915465 A NO15915465 A NO 15915465A NO 118375 B NO118375 B NO 118375B
- Authority
- NO
- Norway
- Prior art keywords
- lower alkyl
- rifamycin
- formyl
- hydroxy
- oxygen
- Prior art date
Links
- BBNQHOMJRFAQBN-UPZFVJMDSA-N 3-formylrifamycin sv Chemical compound OC1=C(C(O)=C2C)C3=C(O)C(C=O)=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BBNQHOMJRFAQBN-UPZFVJMDSA-N 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229940109171 rifamycin sv Drugs 0.000 claims description 12
- -1 morpholinoethoxy, phenyl Chemical group 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- JEHCHYAKAXDFKV-UHFFFAOYSA-J lead tetraacetate Chemical compound CC(=O)O[Pb](OC(C)=O)(OC(C)=O)OC(C)=O JEHCHYAKAXDFKV-UHFFFAOYSA-J 0.000 claims description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- 150000001241 acetals Chemical class 0.000 claims description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims 2
- 101100129500 Caenorhabditis elegans max-2 gene Proteins 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 125000004202 aminomethyl group Chemical class [H]N([H])C([H])([H])* 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000001429 visible spectrum Methods 0.000 description 9
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 238000002211 ultraviolet spectrum Methods 0.000 description 8
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 description 5
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- SQTCRTQCPJICLD-KTQDUKAHSA-N rifamycin B Chemical compound OC1=C(C(O)=C2C)C3=C(OCC(O)=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O SQTCRTQCPJICLD-KTQDUKAHSA-N 0.000 description 4
- SQTCRTQCPJICLD-OQQFTUDCSA-N rifomycin-B Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(OCC(=O)O)c4c3C2=O SQTCRTQCPJICLD-OQQFTUDCSA-N 0.000 description 4
- 229930189077 Rifamycin Natural products 0.000 description 3
- RAFHKEAPVIWLJC-OQQFTUDCSA-N Rifamycin O Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC5(OCC(=O)O5)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C RAFHKEAPVIWLJC-OQQFTUDCSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- RAFHKEAPVIWLJC-TWYIRNIGSA-N z67lem9p1w Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N2)C)OC)C(C(=C3O)C)=C1C1=C3C(=O)C2=C[C@]11OCC(=O)O1 RAFHKEAPVIWLJC-TWYIRNIGSA-N 0.000 description 3
- RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 2
- 229940067157 phenylhydrazine Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960003292 rifamycin Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- CRQRORLRKWVTQE-DTGFBXAHSA-N 3-pyrrolidino-methyl rifamycin sv Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2CN1CCCC1 CRQRORLRKWVTQE-DTGFBXAHSA-N 0.000 description 1
- RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 description 1
- ZETHHMPKDUSZQQ-UHFFFAOYSA-N Betulafolienepentol Natural products C1C=C(C)CCC(C(C)CCC=C(C)C)C2C(OC)OC(OC)C2=C1 ZETHHMPKDUSZQQ-UHFFFAOYSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- HEOKFDGOFROELJ-UHFFFAOYSA-N diacetal Natural products COc1ccc(C=C/c2cc(O)cc(OC3OC(COC(=O)c4cc(O)c(O)c(O)c4)C(O)C(O)C3O)c2)cc1O HEOKFDGOFROELJ-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47F—SPECIAL FURNITURE, FITTINGS, OR ACCESSORIES FOR SHOPS, STOREHOUSES, BARS, RESTAURANTS OR THE LIKE; PAYING COUNTERS
- A47F5/00—Show stands, hangers, or shelves characterised by their constructional features
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
- G09F5/00—Means for displaying samples
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB30327/64A GB1109631A (en) | 1964-07-31 | 1964-07-31 | Derivatives of rifamycin sv |
| FR63914A FR5518M (it) | 1964-07-31 | 1966-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO118375B true NO118375B (it) | 1969-12-22 |
Family
ID=26171063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO159154A NO118375B (it) | 1964-07-31 | 1965-07-30 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US3342810A (it) |
| BE (1) | BE667697A (it) |
| BR (1) | BR6571577D0 (it) |
| CH (1) | CH458353A (it) |
| DE (1) | DE1595883A1 (it) |
| DK (1) | DK115993B (it) |
| FI (1) | FI45044C (it) |
| FR (2) | FR5518M (it) |
| IL (1) | IL23930A (it) |
| NL (1) | NL6509961A (it) |
| NO (1) | NO118375B (it) |
| SE (3) | SE329895B (it) |
| YU (2) | YU32700B (it) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH536851A (de) * | 1966-10-25 | 1973-05-15 | Ciba Geigy Ag | Verfahren zur Herstellung neuer antibiotisch wirksamer Verbindungen der Rifamycinreihen |
| GB1165179A (en) * | 1966-10-25 | 1969-09-24 | Lepetit Spa | Derivatives of Rifamycin SV |
| GB1159267A (en) * | 1966-11-03 | 1969-07-23 | Lepetit Spa | Rifamycin Derivatives |
| US3542762A (en) * | 1967-06-07 | 1970-11-24 | Lepetit Spa | Process for rifamycins |
| FR2059967A1 (it) * | 1969-08-06 | 1971-06-11 | Lepetit Spa | |
| IL39305A (en) * | 1971-06-07 | 1975-08-31 | Lepetit Spa | O-substituted oximes of 3-formylrifamycin sv |
| US3933800A (en) * | 1971-06-07 | 1976-01-20 | Gruppo Lepetit S.P.A. | New 3-formylrifamycin SV derivatives |
| GB1336399A (en) * | 1971-06-24 | 1973-11-07 | Lepetit Spa | 3-formylrifamycin sv derivatives |
| US4005076A (en) * | 1971-06-24 | 1977-01-25 | Gruppo Lepetit S.P.A. | Hydrazones of 3-formylrifamycin SV |
| BE794100A (fr) * | 1972-02-23 | 1973-05-16 | Lepetit Spa | Derives 3-hydrazonomethyles de rifamycine et leur preparation |
| AR205434A1 (es) * | 1972-03-27 | 1976-05-07 | Lepetit Spa | Proceso para la preparacion de 3-acilhidrazonometil rifamicinas sv |
| AR207763A1 (es) * | 1973-07-25 | 1976-10-29 | Archifar Ind Chim Trentino | Metodo para la preparacion de 1,3-oxacino(5,6-c)rifamicinas |
| GB1478563A (en) * | 1975-03-05 | 1977-07-06 | Lepetit Spa | Rifamycin derivatives |
| GB1486118A (en) * | 1975-03-05 | 1977-09-21 | Lepetit Spa | Rifamycin derivatives |
| IT1056271B (it) * | 1975-05-20 | 1982-01-30 | Archifar Ind Chim Trentino | Prodotti derivati dalle amine aromatiche |
| US4179439A (en) * | 1977-07-01 | 1979-12-18 | Intreprinderea De Antibiotice Iasi | Rifamycins and method for their preparation |
| US4150023A (en) * | 1977-07-01 | 1979-04-17 | Intreprinderea De Antibiotice Iasi | Hydrosoluble rifamycins and process for their preparation |
| GB1594134A (en) * | 1977-11-25 | 1981-07-30 | Holco Investment Inc | Rifamycins |
| IT1090772B (it) * | 1977-12-20 | 1985-06-26 | Alfa Farmaceutici Spa | Derivati della rifamicina e procedimento per la loro preparazione |
| IT1090771B (it) * | 1977-12-20 | 1985-06-26 | Alfa Farmaceutici Spa | Derivati delle 3 carbossirifamicines ed sv e procedimento per la loro preparazione |
| GB1591697A (en) * | 1978-03-09 | 1981-06-24 | Archifar Lab Chim Farm | Process for producing 3-amino-rifamycins s and sv |
| US4292327A (en) * | 1978-08-11 | 1981-09-29 | Johnson Lewis A | Method for treatment of human eye disease |
| US4220657A (en) * | 1978-08-11 | 1980-09-02 | Johnson Lewis A | Method for treatment of human eye disease |
| AU536524B2 (en) * | 1979-06-28 | 1984-05-10 | Gruppo Lepetit S.P.A. | Water soluble hydrozones of 3-formylifamyan |
| US4447432A (en) * | 1981-11-17 | 1984-05-08 | Farmitalia Carlo Erba S.P.A. | Azino rifamycins |
| IT1201963B (it) * | 1983-03-24 | 1989-02-02 | Prodotti Antibiotici Spa | Derivati delle rifamicine e procedimento per la loro preparazione |
| GB8308166D0 (en) * | 1983-03-24 | 1983-05-05 | Erba Farmitalia | Preparation of azinomethyl-rifamycins |
| GB8318072D0 (en) * | 1983-07-04 | 1983-08-03 | Lepetit Spa | Water-soluble rifampicin derivatives |
| MC1617A1 (fr) * | 1983-09-01 | 1985-07-18 | Ciba Geigy Ag | Nouvelles hydrazones polycycliques,procede pour leur preparation |
| US4681938A (en) * | 1984-08-27 | 1987-07-21 | Ciba-Geigy Corporation | Novel polycyclic hydrazones of rifamycins, their manufacture, and their pharmaceutical compositions for treating tuberculosis |
| US4551450A (en) * | 1984-08-27 | 1985-11-05 | Ciba-Geigy Corporation | Rifamycin hydrazones, pharmaceutical compositions containing them and their use |
| US4631290A (en) * | 1985-08-29 | 1986-12-23 | American Home Products Corporation | Method of treating hepatitis |
| US4743619A (en) * | 1985-08-29 | 1988-05-10 | American Home Products Corporation | Method of treating hepatitis |
| MC1819A1 (fr) * | 1985-10-18 | 1988-03-18 | Ciba Geigy Ag | Composes 4-benzyl-piperazinyl substitues |
| US4876258A (en) * | 1987-08-13 | 1989-10-24 | Ciba-Geigy Corporation | Biphenylyl compounds |
| US4916126A (en) * | 1987-09-25 | 1990-04-10 | Ciba-Geigy Corporation | Diacyl derivatives of 4-(trialkylbenzyl)-piperazinyl compounds |
| GB8816620D0 (en) * | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
| US6143740A (en) * | 1996-11-19 | 2000-11-07 | Georgetown University | Heregulin antagonists and methods for their use |
| WO2003045319A2 (en) * | 2001-11-21 | 2003-06-05 | Activbiotics, Inc. | Targeted therapeutics and uses thereof |
| US7820652B2 (en) * | 2003-09-24 | 2010-10-26 | Activbiotics Pharma, Llc | Regimen for the administration of rifamycin-class antibiotics |
| WO2007096703A2 (en) | 2005-08-11 | 2007-08-30 | Targanta Therapeutics Inc. | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
| WO2008008480A2 (en) * | 2006-07-12 | 2008-01-17 | Cumbre Pharmaceuticals Inc. | Nitroheteroaryl-containing rifamycin derivatives |
| US20090275594A1 (en) * | 2008-05-05 | 2009-11-05 | Macielag Mark J | 3-hydrazone piperazinyl rifamycin derivatives useful as antimicrobial agents |
| US8524691B2 (en) | 2008-08-13 | 2013-09-03 | The Medicines Company | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
| RU2591188C2 (ru) | 2010-11-08 | 2016-07-10 | Альбирео Аб | Ингибиторы ibat для лечения заболеваний печени |
| JP6867288B2 (ja) | 2014-07-21 | 2021-04-28 | エーエムディー セラピューティックス エルエルシー | リファマイシンの眼科用組成物およびその使用 |
| EP3534910A4 (en) * | 2016-10-04 | 2020-11-25 | Pop Test Oncology LLC | THERAPEUTICS AND PROCEDURES |
| US11702443B2 (en) * | 2016-10-04 | 2023-07-18 | Pop Test Oncology Llc | Therapeutic agents and methods |
-
0
- FR FR208D patent/FR208F/fr active Active
-
1965
- 1965-07-09 US US470926A patent/US3342810A/en not_active Expired - Lifetime
- 1965-07-12 IL IL23930A patent/IL23930A/xx unknown
- 1965-07-13 DK DK357265AA patent/DK115993B/da unknown
- 1965-07-26 BR BR171577/65A patent/BR6571577D0/pt unknown
- 1965-07-27 FI FI651805A patent/FI45044C/fi active
- 1965-07-27 CH CH1053265A patent/CH458353A/fr unknown
- 1965-07-28 DE DE19651595883 patent/DE1595883A1/de active Pending
- 1965-07-30 NL NL6509961A patent/NL6509961A/xx unknown
- 1965-07-30 SE SE10029/65A patent/SE329895B/xx unknown
- 1965-07-30 SE SE13901/68A patent/SE329850B/xx unknown
- 1965-07-30 SE SE13902/68A patent/SE329851B/xx unknown
- 1965-07-30 NO NO159154A patent/NO118375B/no unknown
- 1965-07-30 BE BE667697A patent/BE667697A/xx unknown
-
1966
- 1966-06-02 FR FR63914A patent/FR5518M/fr not_active Expired
-
1968
- 1968-01-04 YU YU0012/68A patent/YU32700B/xx unknown
- 1968-01-04 YU YU0011/68A patent/YU31937B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE329850B (it) | 1970-10-26 |
| YU1268A (en) | 1974-12-31 |
| YU31937B (en) | 1974-02-28 |
| FI45044C (fi) | 1972-03-10 |
| FI45044B (it) | 1971-11-30 |
| FR5518M (it) | 1967-11-06 |
| CH458353A (fr) | 1968-06-30 |
| FR208F (it) | |
| YU1168A (en) | 1973-08-31 |
| SE329851B (it) | 1970-10-26 |
| US3342810A (en) | 1967-09-19 |
| NL6509961A (it) | 1966-02-01 |
| BE667697A (it) | 1965-11-16 |
| BR6571577D0 (pt) | 1973-08-14 |
| DK115993B (da) | 1969-12-01 |
| SE329895B (it) | 1970-10-26 |
| YU32700B (en) | 1975-06-30 |
| DE1595883A1 (de) | 1970-02-12 |
| IL23930A (en) | 1969-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO118375B (it) | ||
| Turan‐Zitouni et al. | Synthesis of Some 1‐[(N, N‐Disubstituted thiocar bamoylthio) acetyl]‐3‐(2‐thienyl)‐5‐aryl‐2‐pyrazoline Derivatives and Investigation of Their Antibacterial and Antifungal Activities | |
| US3644363A (en) | 1 4-dioxidoquinoxalinyl nitrones | |
| DE2606265A1 (de) | Camptothecin-derivate | |
| Bhosale et al. | Mesoionic sydnone derivatives: An overview | |
| US4036842A (en) | Process for preparing polycyclic heterocycles having a pyran ring | |
| DE2612155A1 (de) | Nitrofurylpyrazolderivate, verfahren zu deren herstellung und sie enthaltende arzneimittel | |
| Dinner | Cephalosporin degradations | |
| DE2429923A1 (de) | 1-(arylamino)-pyrrole und 1-(arylimino)-pyrrole, verfahren zu ihrer herstellung und mittel, worin diese verbindungen enthalten sind | |
| Padmavathi et al. | Synthesis and bioassay of a new class of heterocycles pyrrolyl oxadiazoles/thiadiazoles/triazoles | |
| US4044130A (en) | Compositions for the control of microorganisms | |
| NO159154B (no) | Utsetningsanordning for redningsfartoey. | |
| DE1795568C3 (de) | 3-Hydroxymethyl-rifamycin SV und Verfahren zu seiner Herstellung. Ausscheidung aus: 1595883 | |
| Sriram et al. | Novel pthalazinyl derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis isocitrate lyase enzyme | |
| Fukumaru et al. | Synthesis and bioactivity of novel acetylenic compounds | |
| El-Gendy et al. | Synthesis and antimicrobial activity of some new 2-indolinone derived oximes and spiro-isoxazolines | |
| US3957766A (en) | Novel nitrofuran compounds and pharmaceutical compositions | |
| Rinehart Jr et al. | Synthesis of hydrazones and oximes of geldanaldehyde as potential polymerase inhibitors | |
| EP0605493B1 (de) | ANTIALLERGISCHE THIADIAZOLO(4,3-a)PYRIDINDERIVATIVE | |
| JPH0378873B2 (it) | ||
| Hussein et al. | Synthesis and biological activities of some new derivatives based on bis (4, 4'-diamino phenoxy) ethane containing Oxazpines, Terazole rings | |
| DE2522669A1 (de) | Antimikrobielle verbindungen und sie enthaltende zusammensetzungen | |
| NO126453B (it) | ||
| US3631175A (en) | Derivatives of pyrano(3 2-d)oxazole | |
| Elinson et al. | An expedient cyclization of polyfunctional (aryl)(pyrimidinyl)(pyranyl) methanes into spiro [furo [3, 2-c] pyran-2, 5’-pyrimidine] scaffold |